March 19, 2026
Informational only. This content is not legal advice.
In mid-March 2026, the Food and Drug Administration (FDA) took a long-awaited step that signals a new era for the hemp-derived product market. The agency submitted a document titled "Cannabidiol (CBD) Products Compliance and Enforcement Policy" to the White House Office of Information and Regulatory Affairs (OIRA). This move represents the first concrete federal framework for FDA CBD enforcement policy 2026 since the passage of the 2018 Farm Bill. For brands that have operated in a regulatory gray area for nearly eight years, this submission is a clear signal that the period of "enforcement discretion" is coming to an end.
The submission to OIRA is more than just a procedural hurdle; it is a declaration of intent. While the FDA has previously issued warning letters to companies making egregious health claims, it has lacked a comprehensive, unified policy for the broader CBD market. The upcoming policy is expected to outline exactly how the agency will prioritize its enforcement actions, providing a roadmap for CBD product compliance that brands must follow to avoid costly legal battles and product seizures.
Before any significant federal guidance or rule can be issued, it must undergo a review by OIRA, which is part of the Office of Management and Budget (OMB). The OIRA cannabis review process is designed to ensure that the proposed policy is consistent with the administration's priorities and that its economic impact has been properly considered. Typically, this review period lasts up to 90 days, though it can be expedited or extended depending on the complexity of the issue.
The fact that the FDA has reached this stage suggests that the internal drafting of the policy is complete. During the OIRA review, stakeholders may have the opportunity to meet with OMB officials to express their concerns or support for the policy. For CBD brands, this is the final window to understand the direction of federal regulation before it becomes official. The acceleration of this process may have been influenced by the Trump administration's December 2025 executive order on medical marijuana research, which signaled a desire for more clarity in the cannabinoid space.
While the full text of the policy remains confidential during the OIRA review, we can infer the agency's likely priorities based on previous workshops, public statements, and warning letters. The FDA cannabidiol enforcement strategy is expected to focus on several key areas that have long been points of contention between the agency and the industry.
The FDA has consistently maintained that CBD cannot be marketed as a treatment for specific diseases without going through the drug approval process. The 2026 policy will likely double down on this stance. Brands that claim their products can treat anxiety, chronic pain, or sleep disorders without clinical evidence will be at the top of the enforcement list. This includes not just direct claims on labels, but also "implied" claims found in blog posts, social media testimonials, and meta tags.
A major concern for the FDA is the consistency and safety of CBD products. We expect the new policy to emphasize adherence to Current Good Manufacturing Practices (cGMP). This means that brands must be able to prove that their products are free from contaminants like heavy metals, pesticides, and residual solvents. Furthermore, the actual CBD content must match what is stated on the label. Products that are found to be significantly over or under their stated potency will likely face enforcement action.
The question of whether CBD can be legally marketed as a dietary supplement has been a central conflict since 2018. The FDA has previously argued that because CBD was first investigated as a drug (Epidiolex), it cannot be a supplement under the "drug exclusion" rule. The 2026 policy may provide a pathway for CBD to be treated as a new dietary ingredient (NDI), but it will likely come with strict requirements for safety data and notification. Brands should prepare for a more rigorous CBD dietary supplement regulation environment that mirrors the requirements for other botanical supplements.
With the OIRA review underway, brands have a narrow window to get their houses in order. Waiting for the final policy to be published before taking action is a high-risk strategy. Instead, operators should implement a pre-compliance program immediately.
Consider the following checklist for your brand:
Staying informed is critical during this transition. Reports from outlets like Marijuana Moment and Cannabis Law Report provide essential updates on the progress of the OIRA review. Furthermore, clinical perspectives from organizations like the CED Clinic can help brands understand the safety and efficacy standards the FDA is likely to demand.
It is also important to distinguish between "enforcement discretion guidance" and "formal rulemaking." The document currently at OIRA appears to be a guidance document, which means it outlines the agency's current thinking and enforcement priorities but does not have the same force of law as a formal regulation. However, in practice, the FDA treats its guidance as the standard for compliance, and ignoring it is a recipe for disaster.
Once the OIRA review is complete, the FDA will publish the final policy. At that point, the industry will have a clear set of rules to follow. For those who have already taken steps toward CBD product compliance, this will be a moment of validation. For those who have ignored the warning signs, it will be a period of frantic and expensive adjustment.
The enforcement priorities are likely to follow a phased approach:
The FDA CBD enforcement policy 2026 is not a threat to the industry's existence, but it is a threat to the "Wild West" business model. By embracing transparency, safety, and rigorous compliance now, your brand can build the trust with consumers and regulators that is necessary for long-term success in the cannabinoid market. The era of uncertainty is ending; the era of accountability has begun.
